Conference Coverage

Survey Spotlights Identification of Dermatologic Adverse Events From Cancer Therapies

Publish date: May 13, 2024

 

FROM AAD 2024

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Oncologists Voice Ethical Concerns Over AI in Cancer Care
MDedge Hematology and Oncology
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
MDedge Hematology and Oncology
Adding ACEI to Chemotherapy Does Not Prevent Cardiotoxicity
MDedge Hematology and Oncology
Keratoacanthoma, SCC Relatively Rare With PD-1/PD-L1 Inhibitors, Study Suggests
MDedge Hematology and Oncology
The Long, Controversial Search for a ‘Cancer Microbiome’
MDedge Hematology and Oncology
Terminal Cancer: What Matters to Patients and Caregivers
MDedge Hematology and Oncology
Do Health-Related Social Needs Raise Mortality Risk in Cancer Survivors?
MDedge Hematology and Oncology
Do Patients Benefit from Cancer Trial Participation?
MDedge Hematology and Oncology
Can a Risk Score Predict Kidney Injury After Cisplatin?
MDedge Hematology and Oncology
New mRNA Vaccines in Development for Cancer and Infections
MDedge Hematology and Oncology